Actinogen Medical (ASX:ACW) EPS (Basic) : A$-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical EPS (Basic)?

Actinogen Medical's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was A$-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

Actinogen Medical's EPS (Diluted) for the six months ended in Dec. 2023 was A$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

Actinogen Medical's EPS without NRI for the six months ended in Dec. 2023 was A$-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Actinogen Medical EPS (Basic) Historical Data

The historical data trend for Actinogen Medical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical EPS (Basic) Chart

Actinogen Medical Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EPS (Basic)

Get a 7-Day Free Trial

-0.01

Actinogen Medical Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-	-	-	-	-0.01

Actinogen Medical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Actinogen Medical's Basic EPS for the fiscal year that ended in Jun. 2023 is calculated as

Basic EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-10.752	-	0)	/	1875.607
	=	-0.01

Actinogen Medical's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-11.557	-	0)	/	2063.689
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

Actinogen Medical (ASX:ACW) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Actinogen Medical EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinogen Medical (ASX:ACW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

3AC:Germany

Address

109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000

Website

https://www.actinogen.com.au

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (ASX:ACW) Headlines

From GuruFocus

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish • 10-13-2014

Stocks That Are Making A Good Come Back

By reports.droy reports.droy • 03-10-2015